0453 GMT - Citi analyst Mathieu Chevrier would like more details on Ebos's acquisition of pet-medicine provider SVS. Chevrier tells clients in a note that the acquisition is in line with the pharmaceuticals supplier's long-standing M&A strategy, but that the New Zealand-based company didn't provide information on anticipated synergies, capital intensity or how SVS performed prior to the Covid-driven surge in pet ownership. Chevrier expects SVS, combined with Ebos's acquisition of the remaining 10% stake in its Transmedic unit, to be 1%-2% accretive to his fiscal 2026 EPS estimate. Citi has a sell rating and A$32.00 target price on Ebos's Australia-listed stock, which is down 5.1% at A$33.74. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 11, 2025 00:53 ET (04:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。